Work

Outcome of Premature Infants Treated With Chemotherapy for Neuroblastoma in France

Year: 2025

Type: article

Abstract: Neuroblastoma is the most common extracranial solid tumor in children, and congenital forms account for 5% of all neuroblastoma cases. In utero diagnosis is very rare, and the progression leading to premature delivery for urgent treatment is exceptional. In some of these cases, chemotherapy is required after birth, given tumor progression that threatens the functional prognosis (dumbbell neuroblastoma), or even survival (Stage MS). However, the optimal doses of chemotherapy in premature newborns are not known. We present a retrospective cohort of six patients treated in French pediatric oncology centers in order to analyze treatment modalities, and report on their tolerance (five Grade 4 hematological toxicity, three septicemias) as well as the outcome of these newborns (two deaths, four remissions).

Source: Pediatric Blood & Cancer

DOI: 10.1002/pbc.32027

Authors: Dana Al Khalifa, Pascal Chastagner, Gudrun Schleiermacher, Julien Lejeune

Institutions: Centre Hospitalier Régional et Universitaire de Nancy, Institut Curie, Université de Tours, Centre Hospitalier Universitaire de Tours

Language: English

Topic: Neuroblastoma Research and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,640